On August 26, 2025, Eli Lilly and Company announced that their small molecule GLP-1 receptor agonist, Orforglipron, achieved positive results in the third phase 3 clinical trial, ATTAIN-2. Read More

This article examines the global accessibility challenges of Lenacapavir, a groundbreaking HIV prevention drug that demonstrated extraordinary efficacy in clinical trials. It contrasts two perspectives: Gilead Sciences claims rapid progress in making the drug available through voluntary licensing agreements with six generic manufacturers for 120 countries, while critics led by Dr. Andrew Hill argue these agreements exclude crucial middle-income countries representing 23% of global HIV infections. The controversy centers on pricing and accessibility, with Hill calculating generic production could cost $40-95 annually per patient versus Gilead's $40,000 treatment price in high-income markets. Critics suggest compulsory licensing may be necessary if Gilead doesn't modify its approach, citing Colombia's 2024 precedent with dolutegravir. The article notes political shifts threaten HIV funding programs, potentially impacting global distribution efforts. Read More

EpimAb Biotherapeutics has successfully implemented the NewCo model through two significant deals in 2024-2025: licensing EMB-06 to Vignette Bio and a T-cell engaging molecule to Juri Biosciences. Read More

Obesity is a global health crisis affecting over 650 million people worldwide. But there's hope on the horizon. Recent breakthroughs in understanding how our gut and pancreatic hormones regulate appetite and blood sugar have led to the development of exciting new medicines to treat obesity and relat Read More

New Approval of Olaparib IndicationOn January 2nd, AstraZeneca and Merck jointly announced that their PARP inhibitor Lynparza® (Generic name: olaparib) has received approval for a new indication in China. Read More

The topic of this report is a long-acting HIV "vaccine" called Lenacapavir, developed by Gilead Sciences in the United States. Read More

We're excited to discuss groundbreaking research on semaglutide, the blockbuster medication that's showing promising potential in the fight against Alzheimer's disease (AD) Read More

At Unibest, we're proud to be the go-to partner for global pharmaceutical companies seeking high-quality active pharmaceutical ingredients (APIs). Our unmatched expertise in sourcing top-tier pharmaceutical ingredients sets us apart. Today, we're sharing our insights on identifying and selecting the Read More

In the recent advancement of pharmaceutical research and development, deuteration has emerged as a powerful tool for enhancing drug properties and creating new opportunities for innovative drug companies. This blog post explores the potential of deuteration and its impact on the pharmaceutical indus Read More